HOME         WEBSITE         SUBSCRIBE           E-GREETINGS   
                               

Tuesday, January 20, 2015

Ministry Of AYUSH Asks For Rs.2,700 Crore Budgetary Allocation For 2015-16, Says Its Minister

Separate Drug Controller For AYUSH On Cards 

Ministry of AYUSH has asked the finance ministry to hike the budgetary allocation for propagation and promotion of AYUSH to an extent of Rs.2,700 crore for fiscal 2015-16 from present level of Rs.400 crore, its Minister of State (IC) Mr. Shripad Yesso Naik said. 

Inaugurating a Conference on “Mainstreaming Ayush: Cultural Heritage for Healing” under aegis of PHD Chamber of Commerce and Industry, the minister also disclosed that the government have an independent drug controller for the AYUSH that will be separated from the drug controller of modern medicine. 

“The drug controller for AYUSH would be provided with sufficient teeth to regulate the AYUSH as per new policy prescription, who would also be provided with a mandate to issue the certificate of pharmaceutical products (COPP) for exports of AYUSH products”, said the minister pointing out that manufacturers of AYUSH would not be required to run from pillar to post to obtain it from the current arrangements. 

“Recruitment rules are being finalized for the new drug controller and cabinet note being finalized for new regulations of AYUSH products under the new AYUSH health policy which would be unveiled very shortly”, Mr. Naik said. 

He indicated that budgetary allocations for AYUSH until now were meager at about Rs.400 crore for fiscal 2014-15 which need to be multiplied in view of the emerging importance of evolving AYUSH and the ministry has already proposed to the finance ministry to take it to the level of Rs.2,700 crore for the next fiscal, beginning April 2015. 

The fresh standards are also being worked out to ensure that quality AYUSH products are made as per new policy prescription so that such products are well tested for their authenticity, credibility and quality. 

In his welcome remarks, senior vice president PHD Chamber Mr. Mahesh Gupta urged the government to enhance the yearly allocation for AYUSH to an extent of 20% of the total health budget allocations so that money generated is utilized for the expansion, diversification and broad basing AYUSH. 

Chairman, AYUSH Committee of PHD Chamber Mr. Pradeep Multani discussed several issues faced by the industry including issues related to COPP – Certificate of Pharmaceutical Products, Skill Development and Training for AYUSH Students, increase in AYUSH budgets, request for a system where export of AYUSH raw materials in not hindered by Forest Department officials of various States, Financial Support for establishment & Upgrade Drug Testing Laboratories. Subsidised Testing fees for micro and small AYUSH industry members to name a few. During his theme address, he focused on the small scale producers and manufacturers of AYUSH products. 
Posted by

Blog Archive

____________________________________________________________________________________________

Disclaimer - All investments in Mutual Funds and securities are subject to market risks and uncertainty of dividend distributions and the NAV of schemes may go up or down depending upon factors and forces affecting securities markets generally. The past performance of the schemes is not necessarily indicative of the future performance and may not necessarily provide a basis for comparison with other investments. Investors are advised to go through the respective offer documents before making any investment decisions. Prospective client(s) are advised to go through all comparable products in offer before taking any investment decisions. Mutual Funds and securities investments are subject to market risks and there is no assurance or guarantee that the objectives of the fund will be achieved. Information gathered & material used in this document is believed to be from reliable sources. Decisions based on the information provided on this newsletter/document are for your own account and risk.


In the preparation of the material contained in this document, Varun Vaid has used information that is publicly available, including information developed in-house. Some of the material used in the document may have been obtained from members/persons other than the Varun Vaid and which may have been made available to Varun Vaid. Information gathered & material used in this document is believed to be from reliable sources. Varun Vaid however does not warrant the accuracy, reasonableness and/or completeness of any information. For data reference to any third party in this material no such party will assume any liability for the same. Varun Vaid does not in any way through this material solicit any offer for purchase, sale or any financial transaction/commodities/products of any financial instrument dealt in this material. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice.


Varun Vaid, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. All recipients of this material should before dealing and/or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. Any person subscribing to or investigating in any product/financial instruments should do soon the basis of and after verifying the terms attached to such product/financial instrument. Financial products and instruments are subject to market risks and yields may fluctuate depending on various factors affecting capital/debt markets. Please note that past performance of the financial products and instruments does not necessarily indicate the future prospects and performance there of. Such past performance may or may not be sustained in future. Varun Vaid, including persons involved in the preparation or issuance of this material may; (a) from time to time, have long or short positions in, and buy or sell the securities mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation in the financial instruments/products/commodities discussed here in or act as advisor or lender / borrower in respect of such securities/financial instruments/products/commodities or have other potential conflict of interest with respect to any recommendation and related information and opinions. The said person may have acted upon and/or in a manner contradictory with the information contained here. No part of this material may be duplicated in whole or in part in any form and or redistributed without the prior written consent of Varun Vaid. This material is strictly confidential to the recipient and should not be reproduced or disseminated to anyone else.


Varun Vaid also does not take any responsibility for the contents of the advertisements published. Readers are advised to verify the contents on their own before acting there upon.


Published Credits goes to following sources & all the mentioned sources as footer below the published material- Bloomberg, Valueresearch Online, Capital Market, Navindia, Franklin Templeton, Kitco, SBI AMC, LIC AMC, JM Financial AMC, HDFC AMC, The Hindu, Business Line, Personal FN, Economic Times, Reuters, Outlook Money, Business Standard, Times of India etc.